Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma

International Archives of Allergy and Immunology

Volumn 161, Issue , 2013, Pages 107-117

  Takaku, Yotaro ^a,b   Soma, Tomoyuki ^a   Nishihara, Fuyumi ^a   Nakagome, Kazuyuki ^a   Kobayashi, Takehito ^a   Hagiwara, Koichi ^a   Kanazawa, Minoru ^a   Nagata, Makoto ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA CARDIOVASCULAR AND RESPIRATORY CENTER   (Japan)

Author keywords

Eosinophilic inflammation; Interleukin 5; Omalizumab; Peripheral blood mononuclear cells

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; INTERLEUKIN 5; IONOMYCIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE; OMALIZUMAB; PHORBOL 13 ACETATE 12 MYRISTATE; THEOPHYLLINE; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; CYTOKINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC ASTHMA; ALLERGIC RHINITIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; EOSINOPHIL; FEMALE; HUMAN; JAPANESE (PEOPLE); MALE; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; ARTICLE; ASTHMA; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880536450     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000350852     Document Type: Conference Paper

References (40)

1. Holgate ST: Pathogenesis of asthma. Clin Exp Allergy 2008; 38:872-897.
2. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM: Human-ization of an antibody directed against IgE. J Immunol 1993; 151:2623-2632.
3. Schulman ES: Development of a monoclonal anti-immunoglobulin E antibody (omali-zumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001; 164:S6-S11.
4. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of Fc (epsilon) RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-1445.
5. Amaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, Kinet JP, Galli SJ: IgE enhances mouse mast cell FcεRI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 1997; 185:663-672.
6. Beck LA, Marcotte GV, MacGlashan D, To-gias A, Saini S: Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004; 114:527-530.
7. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB: Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 2003; 112:1147-1154.
8. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Stein-bach SF, Calatroni A, Togias A, Thompson KM, Szefler SJ, Sorkness CA: Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-1015.
9. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Ca-nonica GW, Hedgecock S, Fox H, Blogg M, Surrey K: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
10. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J: Efficacy of omalizumab, ananti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17:233-240.
11. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
12. Ohta K, Yamaguchi M, Akiyama K, Adachi M, Ichinose M, Takahashi K, Nishimuta T, Morikawa A, Nishima S: Japanese guideline for adult asthma. Allergol Int 2011; 60:115-145.
13. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NIH publication No. 02-3659, revised 2007. http://www.ginasthma.org (accessed 15 July 2012).
14. National Institutes of Health, National Heart, Lung, and Blood Institute: Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH publication No. 07-4051. Washington, Government Printing Office, 2007.
15. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828-1834.
16. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV: Effects of treatment with anti-immu-noglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593.
17. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N, Seybold J: Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493-1499.
18. Louis R, Lau LC, Bron AO, Roldaan AC, Ra-dermecker M, Djukanovic R: The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161:9-16.
19. Green RH, Brightling CE, McKenna S, Harga-don B, Parker D, Bradding P, Wardlaw AJ, Pavord ID: Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721.
20. Melosini L, Dente FL, Bacci E, Bartoli ML, Cianchetti S, Costa F, Di Franco A, Malagrinò L, Novelli F, Vagaggini B, Paggiaro P: Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control. J Asthma 2012; 49:317-323.
21. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft T: Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65.
22. Gill M, Graff GR, Adler AJ, Dweik RA: Validation study of fractional exhaled nitric oxide measurements using a handheld monitoring device. J Asthma 2006; 43:731-734.
23. American Thoracic Society, European Respiratory Society: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-930.
24. Keatings VM, Evans DJ, O'Connor BJ, Barnes PJ: Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax 1997; 52:372-374.
25. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, Sterk PJ: Repot of working group 1: sputum induction. Eur Respir J 2002;(suppl 37):3s-8s.
26. Nagata M, Shibasaki M, Sakamoto Y, Fukuda T, Makino S, Yamamoto K, Dohi Y: Specific immunotherapy reduces the antigen-dependent production of eosinophil chemotactic activity from mononuclear cells in patients with atopic asthma. J Allergy Clin Immunol 1994; 94:160-166.
27. Mohede IC, Van Ark I, Brons FM, Van Oosterhout AJ, Nijkamp FP: Salmeterol inhibits interferon-gamma and interleukin-4 production by human peripheral blood mononuclear cells. Int J Immunopharmacol 1996; 18:193-201.
28. van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF: Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009; 64:72-80
29. Green RH, Brightling CE, McKenna S, Harga-don B, Parker D, Bradding P, Wardlaw AJ, Pavord ID: Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721.
30. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemière C, Pizzichini E, Cartier A, Hussack P, Goldsmith CH, Laviolette M, Parameswaran K, Hargreave FE: Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483-494.
31. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Brad-ding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
32. Noga O, Hanf G, Kunkel G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131:46-52.
33. Robinson DS: The role of the T cell in asthma. J Allergy Clin Immunol 2010; 126:1081-1091.
34. Schroeder JT, Bieneman AP, Chichester KL, Hamilton RG, Xiao H, Saini SS, Liu MC: Decreases in human dendritic cell-dependent T(h)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010; 125:896-901.
35. Simon HU, Plötz S, Simon D, Seitzer U, Braa-then LR, Menz G, Straumann A, Dummer R, Levi-Schaffer F: Interleukin-2 primes eosino-phil degranulation in hypereosinophilia and Wells syndrome. Eur J Immunol 2003; 33: 834-839.
36. Troye-Blomberg M, Riley EM, Kabilan L, Holmberg M, Perlmann H, Andersson U, Heusser CH, Perlmann P: Production by activated human T cells of interleukin 4, but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens. Proc Natl Acad Sci USA 1990; 87:5484-5488.
37. Surcel HM, Troye-Blomberg M, Paulie S, An-dersson G, Moreno C, Pasvol G, Ivanyi J: Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 1994; 81:171-176.
38. Mori A, Kaminuma O, Mikami T, Inoue S, Okumura Y, Akiyama K, Okudaira H: Tran-scriptional control of the IL-5 gene by human helper T cells: IL-5 synthesis is regulated independently from IL-2 or IL-4 synthesis. J Allergy Clin Immunol 1999; 103:S429-S436.
39. Mori A, Kaminuma O, Suko M, Mikami T, Nishizaki Y, Ohmura T, Hoshino A, Asakura Y, Miyazawa K, Ando T, Okumura Y, Yama-moto K, Okudaira H: Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: a study with allergen-specific human helper T cells. J Allergy Clin Immunol 1997; 100:S56-S64.
40. Ogawa K, Kaminuma O, Kikkawa H, Akiya-ma K, Mori A: IL-5 synthesis by T cells of allergic subjects is regulated at the transcrip-tional level. Int Arch Allergy Immunol 2000; 122:63-66.